Screener
Allogene Therapeutics ALLO Business Segments — Cema-cel
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept allo:ResearchAndDevelopmentExpenseCemaCel.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Significant operating expenses: | ||
| Cema-cel | $7,669 | $6,222 |
| All other development costs | 1,999 | 10,390 |
| Payroll | 14,444 | 19,601 |
| Facilities & IT-related spend | 6,418 | 7,319 |
| Supporting external spend | 4,372 | 5,846 |
| Other operating expenses | 11,190 | 15,813 |
| Total operating expenses | 46,092 | 65,191 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's business segments — cema-cel?
- Allogene Therapeutics (ALLO) reported business segments — cema-cel of $7.67M in Q1 2026.
- How has Allogene Therapeutics's business segments — cema-cel changed year-over-year?
- Allogene Therapeutics's business segments — cema-cel increased by 23.3% year-over-year, from $6.22M to $7.67M.
- What is the long-term trend for Allogene Therapeutics's business segments — cema-cel?
- Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — cema-cel has grown at a -26.5% compound annual growth rate (CAGR), from $43.23M to $23.37M.
- What does business segments — cema-cel mean?
- This metric represents the direct research and development expenditures specifically allocated to the Cema-cel clinical program. It tracks the capital intensity of this lead asset as it progresses through clinical trials. Monitoring these costs helps investors assess the company's investment commitment to its primary therapeutic candidate.
Ask your AI about Allogene Therapeutics's business segments — cema-cel.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude